Pleuroperitoneal fluid type organ culture medium and method and drug sensitive testing method

A culture method and culture medium technology, applied in the field of organoid culture, can solve the problems of non-cancerous pleural effusion organoid culture methods, differences, operability and good repeatability, and achieve the maintenance of tissue cell specificity and mild effect Effect

CN110129270AActive Publication Date: 2019-08-16ACCURATE INT BIOTECHNOLOGY (GUANGZHOU) CO LTD
6 Cites 9 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2019-08-16

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a pleuroperitoneal fluid type organ culture medium and method and a drug sensitive testing method. The pleuroperitoneal fluid type organ culture medium can effective maintain specificity of tissue cells and characteristics of stem cells and ensure high consistency of genetic typing as well as high similarity of tissue shape. Besides meeting the demands of scientific research, the pleuroperitoneal fluid type organ culture medium can be applied to the aspect of clinical medication guidance, and through in vitro organ culture, provide patients with a beneficial option on medication guidance.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of organoid culture, and further relates to the field of pleural and ascites organoid culture, in particular to a culture medium for 3D culture of residual cancer tissue or cancer cells in the pleural and ascites of tumor patients, a method for culturing organoids and a method for drug sensitivity testing. Background technique

[0002] Cancerous pleural effusion, also known as malignant pleural effusion, is one of the common complications of advanced cancer, and it is also the main clinical symptom or sign of some patients. Severe pleural and ascites can even be life-threatening. The diseases of malignant pleural effusion are common in lung cancer and breast cancer, followed by malignant lymphoma, ovarian cancer, malignant pleural mesothelial carcinoma, esophageal cancer, gastric cancer, cardia cancer and malignant tumors of unknown etiology.

[0003] Surgery is currently the mainstay of treatment for many typ...

Examples

Embodiment 1

[0043] A culture medium component of pleural fluid organoids, the content of each component is as follows: B27, 50X dilution; N-acetylsteine, 2.5mM; EGF, 10ng / ml; Noggin, 100ng / ml; R-spondin 1, 500ng / ml or 30 % Conditioned medium; A83-01, 500nM; FGF10, FGF2, 25ng / ml; Nicotinamide, 10mM; Y-27632, 10μm; Prostaglandin E2, 1μM; SB202190, 10μm;

Embodiment 2

[0045] A preservation solution for pleural and ascites, the content of each component is as follows: B27 (0.5x), Hepes (5mM), dispase II (0.1%), EGF (10ng / ml), N2 (0.5x), Nicotinamide (5mM), Y- 27632 (5 μM), A83-01 (0.5 μM) and SB202190 (5 μM).

Embodiment 3

[0047] After the organoids are cultured, the composition of the digestive juice for collecting and digesting the organoids is DMEM / F12 containing 0.1% trypsin, 0.2% dispaseⅡ, 0.1% collagenaseⅢ, insulin 2.5μg / ml, Hepes0.5M, EGF 10ng / ml.